JP2017507160A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507160A5 JP2017507160A5 JP2016555752A JP2016555752A JP2017507160A5 JP 2017507160 A5 JP2017507160 A5 JP 2017507160A5 JP 2016555752 A JP2016555752 A JP 2016555752A JP 2016555752 A JP2016555752 A JP 2016555752A JP 2017507160 A5 JP2017507160 A5 JP 2017507160A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- amino
- aryl
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 91
- 125000004093 cyano group Chemical group *C#N 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000005843 halogen group Chemical group 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- 125000003107 substituted aryl group Chemical group 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 11
- -1 amino, amino Chemical group 0.000 claims 10
- 125000004104 aryloxy group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 7
- 125000002252 acyl group Chemical group 0.000 claims 5
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 4
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 3
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 208000028185 Angioedema Diseases 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010001580 Albuminuria Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 206010044008 tonsillitis Diseases 0.000 claims 1
- 0 ***c1cccc(NC(c2cc(*)n[n]2-c2ccc(*)cc2)=O)c1 Chemical compound ***c1cccc(NC(c2cc(*)n[n]2-c2ccc(*)cc2)=O)c1 0.000 description 5
- XNDGACONQUBLGK-UHFFFAOYSA-N CC(C)NC(c1ccccc1)c1cc(NC(c2cc(C(F)(F)F)n[n]2-c2cc(CN)ccc2)=O)ccc1 Chemical compound CC(C)NC(c1ccccc1)c1cc(NC(c2cc(C(F)(F)F)n[n]2-c2cc(CN)ccc2)=O)ccc1 XNDGACONQUBLGK-UHFFFAOYSA-N 0.000 description 1
- KUUQISQBYJKFFW-UHFFFAOYSA-N CC1C(C(CCC2CC2)(c2cccnc2)O)=CC=CC1NC(c1cc(C(F)(F)F)n[n]1-c1cc(CN)ccc1)=O Chemical compound CC1C(C(CCC2CC2)(c2cccnc2)O)=CC=CC1NC(c1cc(C(F)(F)F)n[n]1-c1cc(CN)ccc1)=O KUUQISQBYJKFFW-UHFFFAOYSA-N 0.000 description 1
- KIDPOTSBLNZGML-UHFFFAOYSA-N CCC(CO)NC(c1ccccc1)c1cccc(NC(c2cc(C(F)(F)F)n[n]2-c2cc(CN)ccc2)=O)c1 Chemical compound CCC(CO)NC(c1ccccc1)c1cccc(NC(c2cc(C(F)(F)F)n[n]2-c2cc(CN)ccc2)=O)c1 KIDPOTSBLNZGML-UHFFFAOYSA-N 0.000 description 1
- HEQLXMARFGMGBQ-UHFFFAOYSA-N COC(CCC1CC1)(c1cc(NC(c2cc(C(F)(F)F)n[n]2-c2cc(CN)ccc2)=O)ccc1)c1cccnc1 Chemical compound COC(CCC1CC1)(c1cc(NC(c2cc(C(F)(F)F)n[n]2-c2cc(CN)ccc2)=O)ccc1)c1cccnc1 HEQLXMARFGMGBQ-UHFFFAOYSA-N 0.000 description 1
- YOBACLFKAGKOLX-UHFFFAOYSA-N COc1c(cccc2)c2c(C(c2cc(NC(c3cc(C(F)(F)F)n[n]3-c3cc(CN)ccc3)=O)ccc2)NCC2CC2)cc1 Chemical compound COc1c(cccc2)c2c(C(c2cc(NC(c3cc(C(F)(F)F)n[n]3-c3cc(CN)ccc3)=O)ccc2)NCC2CC2)cc1 YOBACLFKAGKOLX-UHFFFAOYSA-N 0.000 description 1
- XVOUQCJHWNZPKF-UHFFFAOYSA-N COc1ccc(cccc2)c2c1C(c1cc(NC(c2cc(C(F)(F)F)n[n]2-c2cc(CN)ccc2)=O)ccc1)NCC1CC1 Chemical compound COc1ccc(cccc2)c2c1C(c1cc(NC(c2cc(C(F)(F)F)n[n]2-c2cc(CN)ccc2)=O)ccc1)NCC1CC1 XVOUQCJHWNZPKF-UHFFFAOYSA-N 0.000 description 1
- XEAXHMDONDJJBQ-UHFFFAOYSA-N CS(c1ccccc1C(c1cc(NC(c2cc(C(F)(F)F)n[n]2-c2cc(CN)ccc2)=O)ccc1)NCC1CC1)(=O)=O Chemical compound CS(c1ccccc1C(c1cc(NC(c2cc(C(F)(F)F)n[n]2-c2cc(CN)ccc2)=O)ccc1)NCC1CC1)(=O)=O XEAXHMDONDJJBQ-UHFFFAOYSA-N 0.000 description 1
- GPDBDHGXUBYWPY-UHFFFAOYSA-N Cc(cc1C(Nc2cccc(C(c3ccccc3)NCC3CC3)c2)=O)n[n]1-c1cc(CN)ccc1 Chemical compound Cc(cc1C(Nc2cccc(C(c3ccccc3)NCC3CC3)c2)=O)n[n]1-c1cc(CN)ccc1 GPDBDHGXUBYWPY-UHFFFAOYSA-N 0.000 description 1
- NQOSRSVLDYDVDI-UHFFFAOYSA-N Cc1c(C(c2cc(NC(c3cc(C(F)(F)F)n[n]3-c3cc(CN)ccc3)=O)ccc2)NCC2CC2)cccc1 Chemical compound Cc1c(C(c2cc(NC(c3cc(C(F)(F)F)n[n]3-c3cc(CN)ccc3)=O)ccc2)NCC2CC2)cccc1 NQOSRSVLDYDVDI-UHFFFAOYSA-N 0.000 description 1
- PPHLPILJSQAZAY-UHFFFAOYSA-N Cc1ccc(C(c2cc(NC(c3cc(C(F)(F)F)n[n]3-c3cc(CN)ccc3)=O)ccc2)NCC2CC2)c(C)c1 Chemical compound Cc1ccc(C(c2cc(NC(c3cc(C(F)(F)F)n[n]3-c3cc(CN)ccc3)=O)ccc2)NCC2CC2)c(C)c1 PPHLPILJSQAZAY-UHFFFAOYSA-N 0.000 description 1
- NFGQIHGOUUFZHN-UHFFFAOYSA-N Cc1ccc(C)c(C(c2cc(NC(c3cc(C(F)(F)F)n[n]3-c3cc(CN)ccc3)=O)ccc2)NCC2CC2)c1 Chemical compound Cc1ccc(C)c(C(c2cc(NC(c3cc(C(F)(F)F)n[n]3-c3cc(CN)ccc3)=O)ccc2)NCC2CC2)c1 NFGQIHGOUUFZHN-UHFFFAOYSA-N 0.000 description 1
- CXLXHJIZVQBZJV-UHFFFAOYSA-N NCc1cc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c(c(Cl)c3)ccc3Cl)NCC3CC3)c2)=O)ccc1 Chemical compound NCc1cc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c(c(Cl)c3)ccc3Cl)NCC3CC3)c2)=O)ccc1 CXLXHJIZVQBZJV-UHFFFAOYSA-N 0.000 description 1
- FVRZDZZJKCSOIR-UHFFFAOYSA-N NCc1cc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c3c4OCOc4ccc3)NCC3CC3)c2)=O)ccc1 Chemical compound NCc1cc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c3c4OCOc4ccc3)NCC3CC3)c2)=O)ccc1 FVRZDZZJKCSOIR-UHFFFAOYSA-N 0.000 description 1
- PIDHZVXEDSCGNA-UHFFFAOYSA-N NCc1cc(C(c(cc2)cc(NC(c3cc(C(F)(F)F)n[n]3-c3cc(CN)ccc3)=O)c2F)NCC2CC2)ccc1 Chemical compound NCc1cc(C(c(cc2)cc(NC(c3cc(C(F)(F)F)n[n]3-c3cc(CN)ccc3)=O)c2F)NCC2CC2)ccc1 PIDHZVXEDSCGNA-UHFFFAOYSA-N 0.000 description 1
- AVVDSPSLOYMWMP-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(NC(C2)C=CC=C2C(c2cccc(N)c2)OCC2CC2)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(NC(C2)C=CC=C2C(c2cccc(N)c2)OCC2CC2)=O)c1 AVVDSPSLOYMWMP-UHFFFAOYSA-N 0.000 description 1
- AHHWWBRXILLXFU-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc(cc(C(c(cc2)ccc2C(N)=O)NCC2CC2)cc2)c2F)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc(cc(C(c(cc2)ccc2C(N)=O)NCC2CC2)cc2)c2F)=O)c1 AHHWWBRXILLXFU-UHFFFAOYSA-N 0.000 description 1
- CNAFOXQNPWSINI-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc(cc(C(c2cnccc2)OCC2CC2)cc2)c2F)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc(cc(C(c2cnccc2)OCC2CC2)cc2)c2F)=O)c1 CNAFOXQNPWSINI-UHFFFAOYSA-N 0.000 description 1
- BAOACYBKKSTHLE-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(CCC3CC3)(c3ccccn3)O)c2)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(CCC3CC3)(c3ccccn3)O)c2)=O)c1 BAOACYBKKSTHLE-UHFFFAOYSA-N 0.000 description 1
- OHXCNQRJQHLAER-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c(c(F)ccc3)c3F)NCC3CC3)c2)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c(c(F)ccc3)c3F)NCC3CC3)c2)=O)c1 OHXCNQRJQHLAER-UHFFFAOYSA-N 0.000 description 1
- VZKYGMDBRSVHHT-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c(cc3)cc(Br)c3O)NCC3CC3)c2)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c(cc3)cc(Br)c3O)NCC3CC3)c2)=O)c1 VZKYGMDBRSVHHT-UHFFFAOYSA-N 0.000 description 1
- OTHZVUZOWVKIEI-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c(cc3)ccc3Cl)NCC3CC3)c2)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c(cc3)ccc3Cl)NCC3CC3)c2)=O)c1 OTHZVUZOWVKIEI-UHFFFAOYSA-N 0.000 description 1
- XDCYYWMSVYTRMZ-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c(cc3)ccc3N)NCC3CC3)c2)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c(cc3)ccc3N)NCC3CC3)c2)=O)c1 XDCYYWMSVYTRMZ-UHFFFAOYSA-N 0.000 description 1
- QIBXOBBXVAEMNW-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c(ccc(F)c3)c3F)NCC3CC3)c2)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c(ccc(F)c3)c3F)NCC3CC3)c2)=O)c1 QIBXOBBXVAEMNW-UHFFFAOYSA-N 0.000 description 1
- DGRITJGAWATINU-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c3cc(F)ccc3F)NCC3CC3)c2)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c3cc(F)ccc3F)NCC3CC3)c2)=O)c1 DGRITJGAWATINU-UHFFFAOYSA-N 0.000 description 1
- SZZQZQAYIFWNLF-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c3ccccc3)N(CC3CC3)CC3CC3)c2)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c3ccccc3)N(CC3CC3)CC3CC3)c2)=O)c1 SZZQZQAYIFWNLF-UHFFFAOYSA-N 0.000 description 1
- UCFAODSDUNDTFF-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c3ccccc3)NC3CCC3)c2)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c3ccccc3)NC3CCC3)c2)=O)c1 UCFAODSDUNDTFF-UHFFFAOYSA-N 0.000 description 1
- UQMCUIGBQDUSLW-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c3ccccc3Cl)NCC3CC3)c2)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c3ccccc3Cl)NCC3CC3)c2)=O)c1 UQMCUIGBQDUSLW-UHFFFAOYSA-N 0.000 description 1
- UBQUVYTUKOFUOF-UHFFFAOYSA-N NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c3ccccn3)OCC3CC3)c2)=O)c1 Chemical compound NCc1cccc(-[n]2nc(C(F)(F)F)cc2C(Nc2cccc(C(c3ccccn3)OCC3CC3)c2)=O)c1 UBQUVYTUKOFUOF-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019149385A JP6915003B2 (ja) | 2014-03-07 | 2019-08-16 | ヒト血漿カリクレイン阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461949808P | 2014-03-07 | 2014-03-07 | |
| US61/949,808 | 2014-03-07 | ||
| US201461981515P | 2014-04-18 | 2014-04-18 | |
| US61/981,515 | 2014-04-18 | ||
| PCT/US2015/019535 WO2015134998A1 (en) | 2014-03-07 | 2015-03-09 | Human plasma kallikrein inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149385A Division JP6915003B2 (ja) | 2014-03-07 | 2019-08-16 | ヒト血漿カリクレイン阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507160A JP2017507160A (ja) | 2017-03-16 |
| JP2017507160A5 true JP2017507160A5 (cg-RX-API-DMAC7.html) | 2018-08-09 |
| JP6574435B2 JP6574435B2 (ja) | 2019-09-11 |
Family
ID=54055948
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555752A Active JP6574435B2 (ja) | 2014-03-07 | 2015-03-09 | ヒト血漿カリクレイン阻害剤 |
| JP2019149385A Active JP6915003B2 (ja) | 2014-03-07 | 2019-08-16 | ヒト血漿カリクレイン阻害剤 |
| JP2021116716A Pending JP2021169499A (ja) | 2014-03-07 | 2021-07-14 | ヒト血漿カリクレイン阻害剤 |
| JP2023189564A Pending JP2023181543A (ja) | 2014-03-07 | 2023-11-06 | ヒト血漿カリクレイン阻害剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149385A Active JP6915003B2 (ja) | 2014-03-07 | 2019-08-16 | ヒト血漿カリクレイン阻害剤 |
| JP2021116716A Pending JP2021169499A (ja) | 2014-03-07 | 2021-07-14 | ヒト血漿カリクレイン阻害剤 |
| JP2023189564A Pending JP2023181543A (ja) | 2014-03-07 | 2023-11-06 | ヒト血漿カリクレイン阻害剤 |
Country Status (33)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2712699T3 (es) | 2013-03-25 | 2019-05-14 | Bristol Myers Squibb Co | Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
| SG10201908467RA (en) | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| NO2760821T3 (cg-RX-API-DMAC7.html) | 2014-01-31 | 2018-03-10 | ||
| KR102510427B1 (ko) | 2014-03-07 | 2023-03-14 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| EP3189047B1 (en) | 2014-09-04 | 2018-12-26 | Bristol-Myers Squibb Company | Diamide macrocycles that are fxia inhibitors |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| HRP20220059T1 (hr) | 2015-10-01 | 2022-04-15 | Biocryst Pharmaceuticals, Inc. | Inhibitori kalikreina humane plazme |
| SMT202000382T1 (it) | 2016-05-31 | 2020-09-10 | Kalvista Pharmaceuticals Ltd | Derivati di pirazolo come inibitori di callicreina plasmatica |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| PL3716952T3 (pl) | 2017-11-29 | 2022-05-02 | Kalvista Pharmaceuticals Limited | Postacie dawkowania zawierające inhibitor kalikreiny osoczowej |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| JP7538113B2 (ja) | 2018-08-20 | 2024-08-21 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体ｄ因子の医学的障害の治療のための医薬化合物 |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| AR116951A1 (es) * | 2018-11-02 | 2021-06-30 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| AU2020273154A1 (en) * | 2019-04-08 | 2021-12-02 | Biocryst Pharmaceuticals, Inc. | Plasma kallikrein inhibitors and methods of use thereof in ocular disorders |
| WO2021025969A1 (en) | 2019-08-02 | 2021-02-11 | Teva Pharmaceuticals International Gmbh | Solid state forms of berotralstat |
| WO2021026182A1 (en) | 2019-08-06 | 2021-02-11 | Biocryst Pharmaceuticals, Inc. | Process-scale synthesis of a plasma kallikrein inhibitor |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| EP4017850A1 (en) * | 2019-08-21 | 2022-06-29 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| TW202144331A (zh) * | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| US20250197403A1 (en) | 2020-02-20 | 2025-06-19 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
| CN115210230A (zh) * | 2020-03-04 | 2022-10-18 | 南京明德新药研发有限公司 | 杂环类化合物 |
| KR20230024981A (ko) * | 2020-06-16 | 2023-02-21 | 머크 샤프 앤드 돔 엘엘씨 | 혈장 칼리크레인 억제제 |
| WO2022010828A1 (en) * | 2020-07-10 | 2022-01-13 | Merck Sharp & Dohme Corp. | Plasma kallikrein inhibitors |
| WO2022060842A1 (en) * | 2020-09-15 | 2022-03-24 | The Trustees Of Columbia University In The City Of New York | Systems and methods for predicting graft dysfunction with exosome proteins |
| MX2023009059A (es) | 2021-02-02 | 2023-09-15 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| CN116375648A (zh) * | 2023-03-22 | 2023-07-04 | 苏州农平科技发展有限公司 | 贝罗司他中间体的制备方法 |
| WO2025122555A1 (en) * | 2023-12-05 | 2025-06-12 | Valo Health, Inc. | S1p 1 receptor agonists and uses thereof |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| DE3633840A1 (de) | 1986-10-04 | 1988-04-14 | Hoechst Ag | Phenylpyrazolcarbonsaeurederivate, ihre herstellung und verwendung als pflanzenwachstumsregulatoren und safener |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| CA2049973C (en) | 1990-02-28 | 2002-12-24 | Rodney G. Wolff | Intralumenal drug eluting prosthesis |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| IL130286A0 (en) | 1996-12-23 | 2000-06-01 | Du Pont Pharm Co | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| BR9810151A (pt) * | 1997-06-19 | 2000-08-08 | Du Pont Pharm Co | Composto, composição farmacêutica e método para tratamento ou prevenção de uma desordem tromoboembólica |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| US6271237B1 (en) * | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
| CA2314401A1 (en) * | 1997-12-22 | 1999-07-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
| AU2460600A (en) * | 1999-02-10 | 2000-08-29 | Mitsubishi Pharma Corporation | Amide compounds and medicinal use thereof |
| WO2000059902A2 (en) | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | Aryl sulfonyls as factor xa inhibitors |
| US20010044445A1 (en) | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6329527B1 (en) | 1999-10-21 | 2001-12-11 | Bristol-Myers Squibb Pharma Company | Synthesis of 1,3,5-trisubstituted pyrazoles |
| KR100751981B1 (ko) | 2000-06-27 | 2007-08-28 | 라보라토리오스 살바트, 에스.에이. | 아릴알킬아민으로부터 유도된 카바메이트 |
| AU2001273040A1 (en) * | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| PL366027A1 (en) | 2000-09-22 | 2005-01-24 | Bristol-Myers Squibb Pharma Company | Efficient process for the preparation of a factor xa inhibitor |
| YU79003A (sh) | 2001-04-12 | 2006-05-25 | F. Hoffmann-La Roche Ag. | Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao mglur2 antagonisti ii |
| TWI312274B (en) * | 2001-08-13 | 2009-07-21 | Du Pont | Method for controlling particular insect pests by applying anthranilamide compounds |
| CA2454298A1 (en) * | 2001-08-13 | 2003-02-27 | Gary David Annis | Substituted 1h-dihydropyrazoles, their preparation and use |
| TW200724033A (en) | 2001-09-21 | 2007-07-01 | Du Pont | Anthranilamide arthropodicide treatment |
| BR0212799A (pt) * | 2001-09-21 | 2004-08-03 | Du Pont | Composto, composição e método para o controle de pragas invertebradas |
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| TW200302225A (en) | 2001-12-04 | 2003-08-01 | Bristol Myers Squibb Co | Substituted amino methyl factor Xa inhibitors |
| TW200303309A (en) | 2001-12-04 | 2003-09-01 | Bristol Myers Squibb Co | Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors |
| AU2003241173A1 (en) | 2002-05-24 | 2003-12-12 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
| MXPA04012214A (es) * | 2002-06-13 | 2005-02-25 | Du Pont | Insecticidas de pirazolcarboxamida. |
| DE10229070A1 (de) * | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenylderivate 5 |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| WO2004078732A1 (fr) | 2003-01-28 | 2004-09-16 | Aventis Pharma S.A. | Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation |
| JP4895811B2 (ja) | 2003-09-11 | 2012-03-14 | ケミア，インコーポレイテッド | サイトカイン阻害剤 |
| WO2005094805A1 (ja) * | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
| JP2007532661A (ja) | 2004-04-13 | 2007-11-15 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | アントラニルアミド殺虫剤 |
| US20050272784A1 (en) | 2004-05-07 | 2005-12-08 | Xiaobing Li | Inhibitors of bacterial Type III protein secretion systems |
| US20060069270A1 (en) | 2004-09-27 | 2006-03-30 | Rafael Shapiro | Process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition |
| US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| US20090133318A1 (en) | 2004-11-18 | 2009-05-28 | George Philip Lahm | Anthranilamide insecticides |
| AU2005312721B9 (en) * | 2004-12-07 | 2012-08-02 | Toyama Chemical Co., Ltd. | Novel anthranilic acid derivative or salt thereof |
| US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| GB0516703D0 (en) | 2005-08-15 | 2005-09-21 | Syngenta Participations Ag | Novel insecticides |
| JP5186751B2 (ja) * | 2005-10-14 | 2013-04-24 | 住友化学株式会社 | ヒドラジド化合物およびその有害生物防除用途 |
| BRPI0617221B1 (pt) | 2005-10-14 | 2016-07-12 | Sumitomo Chemical Co | composto de hidrazida, seu uso, pesticida e método de controlar uma peste |
| AR056582A1 (es) | 2005-10-28 | 2007-10-10 | Lilly Co Eli | COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE |
| DK1988777T3 (da) | 2006-02-09 | 2012-01-16 | Athersys Inc | Pyrazoler til behandling af fedme og andre cns-lidelser |
| PE20080702A1 (es) * | 2006-05-16 | 2008-07-10 | Boehringer Ingelheim Int | PROLINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| CA2658523C (en) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| US20100048539A1 (en) | 2006-11-03 | 2010-02-25 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| KR20090094125A (ko) * | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
| WO2008134969A1 (fr) | 2007-04-30 | 2008-11-13 | Sinochem Corporation | Composés benzamides et leurs applications |
| CN101298451B (zh) | 2007-04-30 | 2013-01-30 | 中国中化股份有限公司 | 苯甲酰胺类化合物及其应用 |
| PL2484676T3 (pl) * | 2008-12-18 | 2015-06-30 | Bayer Cropscience Ag | Podstawione tetrazolem amidy kwasu antranilowego jako pestycydy |
| CN102365278B (zh) | 2009-03-26 | 2015-05-06 | 先正达参股股份有限公司 | 杀虫化合物 |
| US8946204B2 (en) | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
| MX2012006913A (es) | 2009-12-18 | 2012-08-23 | Activesite Pharmaceuticals Inc | Profarmacos de inhibidores de calicreina plasmatica. |
| ES2469367T3 (es) | 2010-02-01 | 2014-06-18 | Cancer Research Technology Limited | 1-(5-Terc-butil-2-fenil-2H-pirazol-3-il)-3-[2-fluoro-4-(1-metil-2-oxo-2,3-dihidro-1H-imidazo[4,5-b]piridin-7-iloxi)-fenil]-urea y compuestos relacionados y su uso en terapia |
| JPWO2011118818A1 (ja) | 2010-03-26 | 2013-07-04 | 味の素株式会社 | アミジノアニリン誘導体 |
| CN102285963B (zh) | 2010-06-21 | 2014-04-09 | 中国中化股份有限公司 | 3-甲氧基吡唑酰胺类化合物及其应用 |
| CA2806634A1 (en) | 2010-08-20 | 2012-02-23 | Gruenenthal Gmbh | Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor |
| US20120115903A1 (en) | 2010-11-10 | 2012-05-10 | Gruenenthal Gmbh | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands |
| JP5976778B2 (ja) | 2011-04-11 | 2016-08-24 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体 |
| WO2012142308A1 (en) * | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| WO2013036232A2 (en) | 2011-09-08 | 2013-03-14 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| CA2854424A1 (en) | 2011-11-09 | 2013-05-16 | Grunenthal Gmbh | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an so2-containing group as vanilloid receptor ligands |
| CN103467380B (zh) | 2013-09-29 | 2015-06-24 | 南开大学 | 一类取代苯基吡唑酰胺衍生物及其制备方法和应用 |
| KR102510427B1 (ko) | 2014-03-07 | 2023-03-14 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| AR116951A1 (es) | 2018-11-02 | 2021-06-30 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| WO2021026182A1 (en) | 2019-08-06 | 2021-02-11 | Biocryst Pharmaceuticals, Inc. | Process-scale synthesis of a plasma kallikrein inhibitor |
-
2015
- 2015-03-09 KR KR1020167026786A patent/KR102510427B1/ko active Active
- 2015-03-09 RS RS20201483A patent/RS61159B1/sr unknown
- 2015-03-09 PL PL20191747.3T patent/PL3828173T3/pl unknown
- 2015-03-09 HU HUE15759254A patent/HUE052668T2/hu unknown
- 2015-03-09 RS RS20221083A patent/RS63763B1/sr unknown
- 2015-03-09 EP EP25184854.5A patent/EP4663636A2/en active Pending
- 2015-03-09 SM SM20210031T patent/SMT202100031T1/it unknown
- 2015-03-09 DK DK15759254.4T patent/DK3113772T3/da active
- 2015-03-09 EP EP22191079.7A patent/EP4180424B1/en active Active
- 2015-03-09 EP EP15759254.4A patent/EP3113772B8/en active Active
- 2015-03-09 HR HRP20201916TT patent/HRP20201916T1/hr unknown
- 2015-03-09 KR KR1020237008388A patent/KR102736869B1/ko active Active
- 2015-03-09 ES ES15759254T patent/ES2836373T3/es active Active
- 2015-03-09 JP JP2016555752A patent/JP6574435B2/ja active Active
- 2015-03-09 NZ NZ724250A patent/NZ724250A/en unknown
- 2015-03-09 SG SG10202001795XA patent/SG10202001795XA/en unknown
- 2015-03-09 CN CN201580022369.5A patent/CN106257976B/zh active Active
- 2015-03-09 MX MX2020013059A patent/MX2020013059A/es unknown
- 2015-03-09 ES ES22191079T patent/ES3039514T3/es active Active
- 2015-03-09 DK DK20191747.3T patent/DK3828173T3/da active
- 2015-03-09 EA EA201691803A patent/EA036251B1/ru unknown
- 2015-03-09 MY MYPI2016001634A patent/MY199131A/en unknown
- 2015-03-09 HR HRP20221373TT patent/HRP20221373T1/hr unknown
- 2015-03-09 US US15/123,059 patent/US10125102B2/en active Active
- 2015-03-09 PT PT201917473T patent/PT3828173T/pt unknown
- 2015-03-09 IL IL280785A patent/IL280785B2/en unknown
- 2015-03-09 PT PT157592544T patent/PT3113772T/pt unknown
- 2015-03-09 CA CA3164693A patent/CA3164693A1/en active Pending
- 2015-03-09 SG SG11201607267SA patent/SG11201607267SA/en unknown
- 2015-03-09 PH PH1/2016/501750A patent/PH12016501750B1/en unknown
- 2015-03-09 NZ NZ762034A patent/NZ762034A/en unknown
- 2015-03-09 LT LTEP20191747.3T patent/LT3828173T/lt unknown
- 2015-03-09 SI SI201531442T patent/SI3113772T1/sl unknown
- 2015-03-09 CN CN202110045874.9A patent/CN113307772B/zh active Active
- 2015-03-09 MX MX2016011468A patent/MX377845B/es unknown
- 2015-03-09 PL PL15759254T patent/PL3113772T3/pl unknown
- 2015-03-09 EP EP20191747.3A patent/EP3828173B1/en active Active
- 2015-03-09 ES ES20191747T patent/ES2932406T3/es active Active
- 2015-03-09 WO PCT/US2015/019535 patent/WO2015134998A1/en not_active Ceased
- 2015-03-09 AU AU2015226855A patent/AU2015226855C1/en active Active
- 2015-03-09 MA MA53399A patent/MA53399B1/fr unknown
- 2015-03-09 HU HUE20191747A patent/HUE060660T2/hu unknown
- 2015-03-09 LT LTEP15759254.4T patent/LT3113772T/lt unknown
- 2015-03-09 BR BR112016020199A patent/BR112016020199A8/pt not_active Application Discontinuation
- 2015-03-09 CA CA2941380A patent/CA2941380C/en active Active
- 2015-03-09 SM SM20230002T patent/SMT202300002T1/it unknown
-
2016
- 2016-08-28 IL IL247518A patent/IL247518B/en active IP Right Grant
- 2016-09-13 ZA ZA2016/06320A patent/ZA201606320B/en unknown
-
2018
- 2018-05-11 US US15/977,129 patent/US10329260B2/en active Active
- 2018-06-15 US US16/009,943 patent/US10633345B2/en active Active
-
2019
- 2019-05-01 US US16/400,798 patent/US10689346B2/en active Active
- 2019-08-16 JP JP2019149385A patent/JP6915003B2/ja active Active
-
2020
- 2020-03-24 US US16/828,755 patent/US11192861B2/en active Active
- 2020-03-24 US US16/828,763 patent/US11203574B2/en active Active
- 2020-04-10 US US16/845,833 patent/US11230530B2/en active Active
- 2020-10-27 AU AU2020260400A patent/AU2020260400B2/en active Active
- 2020-12-08 CY CY20201101164T patent/CY1123810T1/el unknown
-
2021
- 2021-07-14 JP JP2021116716A patent/JP2021169499A/ja active Pending
- 2021-10-08 CY CY2021029C patent/CY2021029I2/el unknown
- 2021-10-14 LU LU00233C patent/LUC00233I2/fr unknown
- 2021-10-25 FR FR21C1048C patent/FR21C1048I2/fr active Active
- 2021-10-25 HU HUS2100045C patent/HUS2100045I1/hu unknown
- 2021-10-26 LT LTPA2021524C patent/LTC3113772I2/lt unknown
- 2021-11-01 NL NL301142C patent/NL301142I2/nl unknown
- 2021-11-09 US US17/522,065 patent/US11685721B2/en active Active
- 2021-11-15 US US17/526,377 patent/US11708332B2/en active Active
- 2021-12-07 US US17/543,929 patent/US11708333B2/en active Active
-
2022
- 2022-10-25 AU AU2022259742A patent/AU2022259742B2/en active Active
- 2022-11-07 NO NO2022046C patent/NO2022046I1/no unknown
-
2023
- 2023-04-18 US US18/136,016 patent/US12162838B2/en active Active
- 2023-04-18 US US18/136,025 patent/US12116346B2/en active Active
- 2023-11-06 JP JP2023189564A patent/JP2023181543A/ja active Pending
-
2024
- 2024-09-24 US US18/894,797 patent/US20250257040A1/en active Pending
- 2024-10-11 US US18/913,643 patent/US20250270171A1/en active Pending